A randomized phase III study comparing gemcitabine monotherapy with observation in patients with resected pancreatic cancer

被引：1
|
作者：
Kosuge, T. [1 ]
Ueno, H. [1 ]
Matsuyama, Y. [2 ]
Yamamoto, J. [3 ]
Nakao, A. [4 ]
Egawa, S. [5 ]
Doi, R. [6 ]
Monden, M. [7 ]
Hatori, T. [8 ]
Tanaka, M. [9 ]
机构：
[1] Natl Canc Ctr, Hepatobiliary & Pancreat Surg Div, Tokyo, Japan
[2] Univ Tokyo, Dept Biostat, Tokyo, Japan
[3] Canc Inst Hosp, Dept Gastrointestinal Surg, Tokyo, Japan
[4] Nagoya Univ, Dept Surg 2, Aichi, Japan
[5] Tohoku Univ, Div Gastroenterol, Sendai, Miyagi 980, Japan
[6] Kyoto Univ, Dept Surg, Kyoto, Japan
[7] Osaka Univ, Dept Surg & Clin Oncol, Osaka, Japan
[8] Tokyo Womens Med Univ, Dept Surg, Tokyo, Japan
[9] Kyushu Univ, Dept Surg & Oncol, Fukuoka 812, Japan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71007-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3504
引用
收藏
页码：260 / 260
页数：1
相关论文
共 50 条
  • [21] Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
    Philip Q. Bao
    Ramesh K. Ramanathan
    Alyssa Krasinkas
    Nathan Bahary
    Barry C. Lembersky
    David L. Bartlett
    Steven J. Hughes
    Kenneth K. Lee
    A. James Moser
    Herbert J. Zeh
    Annals of Surgical Oncology, 2011, 18 : 323 - 323
  • [22] A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
    G P Stathopoulos
    K Syrigos
    G Aravantinos
    A Polyzos
    P Papakotoulas
    G Fountzilas
    A Potamianou
    N Ziras
    J Boukovinas
    J Varthalitis
    N Androulakis
    A Kotsakis
    G Samonis
    V Georgoulias
    British Journal of Cancer, 2006, 95 : 587 - 592
  • [23] A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
    Stathopoulos, G. P.
    Syrigos, K.
    Aravantinos, G.
    Polyzos, A.
    Papakotoulas, P.
    Fountzilas, G.
    Potamianou, A.
    Ziras, N.
    Boukovinas, J.
    Varthalitis, J.
    Androulakis, N.
    Kotsakis, A.
    Samonis, G.
    Georgoulias, V.
    BRITISH JOURNAL OF CANCER, 2006, 95 (05) : 587 - 592
  • [24] ESPAC-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma
    Neoptolemos, J. P.
    Palmer, D.
    Ghaneh, P.
    Valle, J.
    Cunningham, D.
    Wadsley, J.
    Meyer, T.
    Anthoney, A.
    Glimelius, B.
    Falk, S.
    Lind, P.
    Izbicki, J.
    Middleton, G.
    Ross, P.
    Wasan, H.
    McDonald, A.
    Crosby, T.
    Psarelli, E.
    Hammel, P.
    Buechler, M. W.
    PANCREAS, 2016, 45 (10) : 1529 - 1529
  • [25] RANDOMIZED PHASE III TRIAL COMPARING ADJUVANT PACLITAXEL/GEMCITABINE/CISPLATIN (PGC) TO OBSERVATION IN PATIENTS WITH RESECTED INVASIVE BLADDER CANCER: RESULTS OF THE SOGUG-GUO-AEU 99/01 TRIAL
    Solsona, E.
    Paz-Ares, L.
    Fernandez, J. M.
    Hevia, M.
    Orsola, A.
    Morote, J.
    Bellmunt, J.
    De La Rosa, F.
    Llorente, C.
    Donas, Jl
    Guillem, V
    Cozar, J. M.
    Ballesteros, P.
    Javaloyas, J.
    Carbonero, J.
    Burgues, J. P.
    Rodriguez Molina, J.
    Gutierrez, J. L.
    Garcia, D.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 212 - 212
  • [26] Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer
    Ueno, Makoto
    Sugimori, Kazuya
    Taguri, Masataka
    Ohkawa, Shinichi
    Kobayashi, Satoshi
    Miwa, Haruo
    Kaneko, Takashi
    Morimoto, Manabu
    Yamanaka, Takeharu
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 74 (01): : 122 - 130
  • [27] Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer.
    Ueno, Makoto
    Kobayashi, Satoshi
    Ohkawa, Shinichi
    Kameda, Ryo
    Andou, Tomoko
    Sugimori, Kazuya
    Miwa, Haruo
    Ko, Ryonho
    Tanaka, Katsuaki
    Taguri, Masataka
    Morita, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks-A prospective randomized phase III study
    Sinn, Marianne
    Liersch, Torsten
    Gellert, Klaus
    Messmann, Helmut
    Bechstein, Wolf O.
    Waldschmidt, Dirk
    Jacobasch, Lutz
    Wilhelm, Martin
    Rau, Bettina M.
    Gruetzmann, Robert
    Weinmann, Arndt
    Maschmeyer, Georg
    Pelzer, Uwe
    Stieler, Jens
    Striefler, Jana Kaethe
    Ghadimi, B. Michael
    Bahra, Marcus
    Oettle, Helmut
    Doerken, Bernd
    Riess, Hanno
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew V.
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian
    GASTROENTEROLOGY, 2015, 148 (04) : S944 - S944
  • [30] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Heinrich, Stefan
    Pestalozzi, Bernhard
    Lesurtel, Mickael
    Berrevoet, Frederik
    Laurent, Stephanie
    Delpero, Jean-Robert
    Raoul, Jean-Luc
    Bachellier, Phillippe
    Dufour, Patrick
    Moehler, Markus
    Weber, Achim
    Lang, Hauke
    Rogiers, Xavier
    Clavien, Pierre-Alain
    BMC CANCER, 2011, 11
12345